FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2603283012> ?p ?o ?g. }

• W2603283012 endingPage "5019" @default.
• W2603283012 startingPage "5019" @default.
• W2603283012 abstract "5019 Background: Chemotherapeutic options for HRPC are limited. S is a novel oral platinum compound. Methods: The SPARC trial is a multinational randomized double blind study comparing S 80 mg/m 2 /day x 5 q5weeks po + prednisone (P) vs placebo + P in HRPC patients (pts) who failed prior chemotherapy. In this analysis, progression-free survival (PFS) was the primary endpoint, defined as a composite endpoint of radiologic progression, symptomatic progression, skeletal events or death. All cases were blindly adjudicated for progression by an independent review committee (IRC). Results: 950 pts were accrued between Sept 2004 and Jan 2006. Baseline characteristics were well balanced between treatment arms. 51% of the pts had received prior docetaxel. 68% were ≥ 65 yrs old and 27% were ≥ 75 yrs old. Pts received a median of 4 courses in the S arm (range:1–28) vs 2 courses in the placebo arm (range 1–16). 802 pts had an IRC defined progression-free (PFS) event consisting in 80% of the cases of radiologic progression, pain progression or death. All analyses were conducted on an intent-to-treat basis. S was associated with a 31% reduction in the risk of PFS events (HR=0.69; 95% CI: 0.60–0.80; p<0.00001) and a 33% reduction in the risk of pain progression (HR=0.67; 95% CI: 0.54 - 0.83; p=0.00028). Consistent results in favor of S were found for PFS and time to pain progression in all subsets examined, including pts treated with prior docetaxel. Superior PSA response (25% vs.12%, p=0.00007), objective tumor response (7% vs. 1%, p<0.002), pain response (24% vs. 14%, p<0.005), and duration of pain response (HR=0.59; 95%CI: 0.35–1.00; p=0.049) were observed for S. Final analysis of overall survival awaits the occurrence of the pre-specified number of events. S was generally well tolerated - myelosuppression was the most frequent side effect, but grade 4 neutropenia was uncommon (4%) and a single patient had grade 4 thrombocytopenia. Grade 3/4 non-hematologic side effects included infection (4%), vomiting (2%) and diarrhea (2%). Conclusions: S is well tolerated and significantly reduces the risk of disease progression for HRPC pts who have failed prior chemotherapy. Supported by GPC Biotech and Pharmion No significant financial relationships to disclose." @default.
• W2603283012 created "2017-04-07" @default.
• W2603283012 creator A5023735057 @default.
• W2603283012 creator A5024101557 @default.
• W2603283012 creator A5035439869 @default.
• W2603283012 creator A5037901541 @default.
• W2603283012 creator A5042114199 @default.
• W2603283012 creator A5050042851 @default.
• W2603283012 creator A5053603129 @default.
• W2603283012 creator A5053950718 @default.
• W2603283012 creator A5056990947 @default.
• W2603283012 creator A5073246821 @default.
• W2603283012 date "2007-06-20" @default.
• W2603283012 modified "2023-10-14" @default.
• W2603283012 title "Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial" @default.
• W2603283012 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.5019" @default.
• W2603283012 hasPublicationYear "2007" @default.
• W2603283012 type Work @default.
• W2603283012 sameAs 2603283012 @default.
• W2603283012 citedByCount "45" @default.
• W2603283012 countsByYear W26032830122012 @default.
• W2603283012 countsByYear W26032830122016 @default.
• W2603283012 countsByYear W26032830122021 @default.
• W2603283012 countsByYear W26032830122022 @default.
• W2603283012 crossrefType "journal-article" @default.
• W2603283012 hasAuthorship W2603283012A5023735057 @default.
• W2603283012 hasAuthorship W2603283012A5024101557 @default.
• W2603283012 hasAuthorship W2603283012A5035439869 @default.
• W2603283012 hasAuthorship W2603283012A5037901541 @default.
• W2603283012 hasAuthorship W2603283012A5042114199 @default.
• W2603283012 hasAuthorship W2603283012A5050042851 @default.
• W2603283012 hasAuthorship W2603283012A5053603129 @default.
• W2603283012 hasAuthorship W2603283012A5053950718 @default.
• W2603283012 hasAuthorship W2603283012A5056990947 @default.
• W2603283012 hasAuthorship W2603283012A5073246821 @default.
• W2603283012 hasConcept C126322002 @default.
• W2603283012 hasConcept C141071460 @default.
• W2603283012 hasConcept C142724271 @default.
• W2603283012 hasConcept C143998085 @default.
• W2603283012 hasConcept C168563851 @default.
• W2603283012 hasConcept C203092338 @default.
• W2603283012 hasConcept C204787440 @default.
• W2603283012 hasConcept C27081682 @default.
• W2603283012 hasConcept C2776694085 @default.
• W2603283012 hasConcept C2778720950 @default.
• W2603283012 hasConcept C2780739268 @default.
• W2603283012 hasConcept C2781190966 @default.
• W2603283012 hasConcept C71924100 @default.
• W2603283012 hasConceptScore W2603283012C126322002 @default.
• W2603283012 hasConceptScore W2603283012C141071460 @default.
• W2603283012 hasConceptScore W2603283012C142724271 @default.
• W2603283012 hasConceptScore W2603283012C143998085 @default.
• W2603283012 hasConceptScore W2603283012C168563851 @default.
• W2603283012 hasConceptScore W2603283012C203092338 @default.
• W2603283012 hasConceptScore W2603283012C204787440 @default.
• W2603283012 hasConceptScore W2603283012C27081682 @default.
• W2603283012 hasConceptScore W2603283012C2776694085 @default.
• W2603283012 hasConceptScore W2603283012C2778720950 @default.
• W2603283012 hasConceptScore W2603283012C2780739268 @default.
• W2603283012 hasConceptScore W2603283012C2781190966 @default.
• W2603283012 hasConceptScore W2603283012C71924100 @default.
• W2603283012 hasIssue "18_suppl" @default.
• W2603283012 hasLocation W26032830121 @default.
• W2603283012 hasOpenAccess W2603283012 @default.
• W2603283012 hasPrimaryLocation W26032830121 @default.
• W2603283012 hasRelatedWork W1967868926 @default.
• W2603283012 hasRelatedWork W2051228185 @default.
• W2603283012 hasRelatedWork W2062742219 @default.
• W2603283012 hasRelatedWork W2080820783 @default.
• W2603283012 hasRelatedWork W2087322859 @default.
• W2603283012 hasRelatedWork W2167650070 @default.
• W2603283012 hasRelatedWork W2351661875 @default.
• W2603283012 hasRelatedWork W2600501716 @default.
• W2603283012 hasRelatedWork W3032029751 @default.
• W2603283012 hasRelatedWork W4238574250 @default.
• W2603283012 hasVolume "25" @default.
• W2603283012 isParatext "false" @default.
• W2603283012 isRetracted "false" @default.
• W2603283012 magId "2603283012" @default.
• W2603283012 workType "article" @default.